HDL-C and stratification of individual risk
Authors:
Rudolf Poledne; Ivana Králová Lesná
Authors‘ workplace:
Laboratoř pro výzkum aterosklerózy, Centrum experimentální medicíny, IKEM, Praha
Published in:
AtheroRev 2019; 4(2): 105-107
Category:
From scholarly literature
Sources
- Enger SC, Hjermann I, Foss OP et al. High density lipoprotein cholesterol and myocardial infarction or sudden coronary death:a prospective case-control study in middle-aged men of the Oslo study. Artery 1979; 5(2): 170–181.
- Gordon DJ, Knoke J, Probstfield JL et al. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the lipid research clinics coronary primary prevention trial. Circulation 1986; 74(6): 1217–1225.
- Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79(1): 8–15.
- Di Angelantonio E, Sarwar N, Perry P et al. [Emerging Risk Factors Collaboration]. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302(18): 1993–2000. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2009.1619>.
- Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 2016; 118(4): 547–563. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.115.306249>.
- Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events, N. Engl. N Engl J Med 2007; 357(21): 2109–2122. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0706628>.
- Schwartz GG, Olsson AG, Abt M et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367(22): 2089–2099. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1206797>.
- Bowman L, Hopewell JC, Chen F et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 2017; 377(13): 1217–1227. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1706444>.
- Lüscher TF, Landmesser U, von Eckardstein A et al. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 2014; 114(1): 171–182. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.114.300935.>.
- Genest J, Choi HY. Novel approaches for HDL-directed therapies. Curr Atheroscler Rep 2017; 19(12): 55. Dostupné z DOI: <http://dx.doi.org/10.1007/s11883–017–0699–1>.
- Holmes MV, Asselbergs FW, Palmer TM et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2015; 36(9): 539–550. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht571>.
- Funke H. Genetic determinants of high density lipoprotein levels. Curr Opin Lipidol 1997; 8(3): 189–196.
- Králová Lesná I, Suchánek P, Stávek P et al. May alcohol-induced increase of HDL be considered as atheroprotective? Physiol Res 2010; 59(3): 407–413.
- Kralova Lesna I, Suchanek P, Kovar J et al. Replacement of dietary saturated FAs by PUFAs in diet and reverse cholesterol transport. J Lipid Res 2008; 49(11): 2414–2418. Dostupné z DOI: <http://dx.doi.org/10.1194/jlr.M800271-JLR200>.
- Králová Lesná I, Suchánek P, Kovár J et al. Life style change and reverse cholesterol transport in obese women. Physiol Res 2009; 58(Suppl 1): S33-S38.
- Barter P, Genest J. HDL cholesterol and ASCVD risk stratification: A debate. Atherosclerosis 2019; 283: 7–12. Dostupné z DOI: <http://doi: 10.1016/j.atherosclerosis.2019.01.001>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2019 Issue 2
Most read in this issue
- The role of bilirubin in diabetes, metabolic syndrome and cardiovascular diseases
- New hypolipidemic agents in the treatment of diabetic dyslipidemia
- Effect of novel anti-diabetic medication on cardiovascular risk
- Hypolipidemic treatment and microvascular complications of diabetes